Hilar cholangiocarcinoma is generally an acquired condition that is not inherited from parents and does not run in families in a Mendelian pattern. The underlying biology involves malignant transformation of bile duct lining cells, but precise molecular mechanisms in any individual case are not well established. Several recognized clinical risk factors increase the likelihood of developing this cancer, including primary sclerosing cholangitis, chronic parasitic liver fluke infection in endemic regions, hepatolithiasis (intrahepatic bile duct stones), choledochal cysts, and chronic biliary inflammation. Most people with these conditions never develop hilar cholangiocarcinoma, and many patients have no identifiable risk factor. Discussions of personal risk should occur with a hepatologist or oncologist.

Diagnosing hilar cholangiocarcinoma typically begins when a patient presents with jaundice or abnormal liver-function blood tests. Cross-sectional imaging — generally contrast-enhanced CT and MRI with magnetic resonance cholangiopancreatography (MRCP) — is used to evaluate the bile duct stricture and assess vascular involvement and tumor extent. Endoscopic retrograde cholangiopancreatography (ERCP) may be used to visualize the biliary tree, obtain brushings or biopsies, and place stents to relieve obstruction. Additional sampling, such as endoscopic ultrasound-guided biopsy, may help confirm the diagnosis. Tumor markers like CA 19-9 are sometimes used as supporting information. Diagnosis is confirmed through a combination of imaging findings and tissue evaluation by a multidisciplinary care team.

Treatment planning for hilar cholangiocarcinoma depends on disease stage, tumor location and extent, biliary anatomy, and overall health. Management typically involves a multidisciplinary oncology team and may include surgery (often with extensive bile duct and partial liver resection) when the tumor is considered resectable, with curative intent. For selected patients with unresectable tumors, liver transplantation following neoadjuvant therapy may be an option at specialized centers. When surgery is not possible, care often centers on relieving bile duct obstruction through endoscopic or percutaneous biliary drainage, alongside systemic treatment approaches, local or regional therapies, and supportive and palliative care. Treatment goals are individualized — curative or focused on disease control and symptom management. Patients should consult their oncology care team.

Outcomes in hilar cholangiocarcinoma depend strongly on disease stage at diagnosis, tumor characteristics, the ability to achieve a complete surgical resection, and response to treatment. Because the tumor lies at a complex anatomic junction near major blood vessels, resectability is a key determinant of long-term outcomes. Patients diagnosed with earlier-stage, resectable disease and those who undergo successful surgery, sometimes followed by adjuvant therapy, tend to have more favorable outcomes than those with locally advanced or metastatic disease at presentation. Survival outcomes overall have improved with advances in surgical techniques, biliary drainage, imaging, and systemic therapy. Early detection and access to specialized hepatobiliary and oncology care can improve outcomes. Individual prognosis should be discussed with the care team.

Hilar cholangiocarcinoma is an active area of research, with several clinical trials currently investigating new approaches. Ongoing studies are exploring neoadjuvant chemoradiotherapy and immunotherapy combinations to convert borderline or unresectable tumors into candidates for surgery, as well as the role of liver transplantation for selected non-resectable tumors. Additional trials are evaluating novel systemic regimens, antibody-drug conjugates, targeted therapies in biliary tract cancers, and adjuvant strategies after surgery. Research also includes biomarker discovery, including blood-based DNA methylation tests for earlier detection, and improved preoperative lymph node assessment. Individuals interested in clinical trials can search ClinicalTrials.gov or consult their care team to identify studies that may be appropriate for their specific situation.